Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Aoxing Pharmaceutical Company, a manufacturer of narcotic and pain-management products, has received a new production license for isosorbide mononitrate injection from the China State Food and Drug Administration for treatment of angina pectoris, myocardial infarction, of chronic congestive heart failure, pulmonary hypertension and related coronary artery disease.
Subscribe to our email newsletter
Juan Han, chairman and CEO of China Aoxing, said: “We are very excited to have another drug approval in year 2009. This approval further underscores China Aoxing’s long-term commitment to developing high quality hospital care therapies. We are looking forward to launching this product in the second half of 2009.”